PTPN11 and prostate carcinoma: Targeting SHP2 increases expression of PD-L1 and human leukocyte antigen (HLA) ABC in prostate cancer cells by phosphorylating STAT1, which is relevant to immune-cell interaction and immunotherapy tactics (145).